Back to today’s briefing

Story perspectives

Biotech's $170B Patent Cliff Fuels Precision Oncology Surge

1/12/2026

36 4

Summary

Story summary

The biotechnology sector faces a $170 billion patent cliff, prompting a shift to late-stage oncology.
The precision oncology market is expected to reach $225.65 billion by 2032.
Oncolytics Biotech Inc. reports pelareorep yields a 29% response rate in anal cancer.
Pyxis Oncology reports a 46% response rate in head and neck cancer.
Enliven Therapeutics shows a 69% major molecular response rate for its CML treatment, highlighting 2026.

1 of 1

Story summary

The biotechnology sector faces a $170 billion patent cliff, prompting a shift to late-stage oncology.
The precision oncology market is expected to reach $225.65 billion by 2032.
Oncolytics Biotech Inc. reports pelareorep yields a 29% response rate in anal cancer.
Pyxis Oncology reports a 46% response rate in head and neck cancer.
Enliven Therapeutics shows a 69% major molecular response rate for its CML treatment, highlighting 2026.